Article PDF first page preview

First page of Association between miR-27a rs895819 polymorphism and antidepressant treatment response in patients with depression

Introduction: Depression is a prevalent mental health disorder. miR-27a regulates neuronal development. This study aimed to investigate the association between the miR-27a rs895819 polymorphism and antidepressant treatment response in patients with depression. Methods: The expression level of miR-27a was detected by reverse transcription-polymerase chain reaction. The genotype of rs895819 was performed by PCR-restriction fragment length polymorphism. The condition of patients was evaluated by a 17-item Hamilton Depression Rating Scale (HAMD-17). Reduction rate = (HAMD-17 baseline- HAMD-17 8 week)/ HAMD-17 baseline × 100%. Effective response was defined as a reduction rate of ≥50%. Remission was defined as HAMD-17 ≤17. The association between SNP and depression risk was calculated by the χ2 test. Logistic regression analysis was performed to evaluate the effects of SNP on antidepressant treatment response. Results: There were 173 patients with depression and 186 healthy controls. rs895819 was negatively correlated with depression under CC vs. TT (P=0.044, OR=0.412, 95%CI=0.170-0.996), CC+TC vs. TT (OR=0.607, 95%CI=0.397-0.927) and C vs. T (OR=0.633, 95%CI=0.448-0.896) models. miR-27a expression was significantly decreased in individuals with TC/CC genotypes than TT genotypes. rs895819 (TC/CC) was positively correlated with the effective response (P=0.005, OR=2.551, 95%CI=1.322-4.920). Conclusion: rs895819 TC/CC genotypes were significantly correlated with depression, and associated with increased effective response.

S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.